netFormulary Bradford Teaching Hospitals NHS
NHS Foundation Trust Formulary  
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
08.01.03  Expand sub section  Antimetabolites
Cytotoxic Drug Azacitidine (Vidaza)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
Link  NICE TA218: azacitidine for myelodysplastic syndromes
   
Cytotoxic Drug Capecitabine (Xeloda)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
Link  NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Link  NICE TA191: Gastric cancer (advanced) - capecitabine
Link  NICE TA60: Colorectal cancer - capecitabine and tegafur uracil
   
Cytotoxic Drug Cladribine
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
   
Cladribine (Litak)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
   
Cytotoxic Drug Clofarabine (Evoltra)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
VIA CDF for following

Acute lymphoblastic leukaemia in patients with relapsed/ refractory disease in whom the intent is to use treatment as a bridge to bone marrow transplantation

Acute Myeloblastic leukaemia in patients with relapsed/ refractory disease in whom the intent is to use treatment as a bridge to bone marrow transplantation
 
   
Cytotoxic Drug Cytarabine
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
   
Cytarabine (DepoCyte)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
   
Cytotoxic Drug Fludarabine Phosphate (Fludara)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
Link  NICE TA119: Leukaemia (lymphocytic) - fludarabine
Link  NICE TA29: Leukaemia (lymphocytic) - fludarabine
   
Cytotoxic Drug Fluorouracil
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
   
Fluorouracil
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
   
Cytotoxic Drug Gemcitabine (Gemzar)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
Link  NICE TA116: Breast cancer - gemcitabine
Link  NICE TA25: Pancreatic cancer - gemcitabine
   
Cytotoxic Drug Mercaptopurine
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
   
Cytotoxic Drug Methotrexate
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary  
Link  UKMI Q&A: alcohol and methotrexate guidance
   
Cytotoxic Drug Pemetrexed (Alimta)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
Maintenance pemetrexed available through the CDF  
Link  NICE TA124: Lung cancer (non-small-cell) - pemetrexed
Link  NICE TA135: Mesothelioma - pemetrexed disodium
Link  NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed
Link  NICE TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance)
   
Cytotoxic Drug Raltitrexed (Tomudex)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
Link  NICE CG131 - Colorectal Cancer: The diagnosis and management of colorectal cancer
   
Cytotoxic Drug Tioguanine (Lanvis)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
   
 ....
 Non Formulary Items
Decitabine  (Dacogen)

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Red
Link  NICE TA270: Leukaemia (acute myeloid ) - decitabine (terminated appraisal) (TA270)
 
Nelarabine  (Atriance)

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Red
 
Cytotoxic Drug  Tegafur with Uracil  (Uftoral)

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Red
Link  NICE TA61: Capcitabine and tegafur - Colorectal cancer
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Amber

Medicines suitable to be prescribed in primary care after Specialist* recommendation or initiation. A supporting prescribing guideline may be requested which must have been agreed by the relevant secondary care trust D&TC(s). *Specialist is defined as a clinician who has undertaken an appropriate formal qualification or recognised training programme within the described area of practice.   

Amber 1

Medicines that should be initiated by a specialist and prescribed by primary care prescribers only under a shared care protocol, once the patient has been stabilised. Prior agreement must be obtained by the specialist from the primary care provider before prescribing responsibility is transferred. The shared care protocol must have been agreed by the relevant secondary care trust Drugs and Therapeutics Committee(s) (D&TC) * All drugs awaiting the production or approval of a shared care guideline default to RED   

Cancer Drug Fund

Cancer Drug Fund   

Green

Medicines suitable for routine use and can be prescribed within primary care within their licensed indication, in accordance with nationally recognised formularies, for example the BNF, BNF for Children, Medicines for Children or Palliative Care Formulary. Primary care prescribers take full responsibility for prescribing.  

Green Specialist Initiation

These drugs should be initiated only by a hospital or specialist clinician (GPSi) but there is no requirement for additional monitoring over the general requirements for all medicines. Some may require short or medium specialist monitoring of efficacy or dose titration before transferring in Primary care. The GP should have all the information they require to support continued prescribing.   

Green Specialist Recomendation

  

Grey

Grey - Medicines, which the Drug & therapeutics Committee has actively reviewed and does not recommend for use at present following a review of clinical and/or cost effective data. Grey (assessment in progress) - will be reviewed at a future D&T meeting. Grey (awaiting submission) - The D&T are awaiting a submission from an appropriate practitioner. If you wish to make a submission for this medicine to be added to the formulary please email drug.information@bthft.nhs.uk .   

Non Formulary

Not recommended for prescribing as initial therapy, but can be continued if patient already stable on treatment   

Red

Medicines which should normally be prescribed by specialists only. ** For patients already receiving prescriptions in primary care - continue. No new patients to receive prescriptions in primary care   

RED ULM

Unlicensed Medication  

netFormulary